The University of Southampton
University of Southampton Institutional Repository

A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response

A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response
A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response

Although a relatively common behavior, treatment data for pathological skin picking (PSP) are limited. The current study sought to examine the efficacy and tolerability of lamotrigine in adults with PSP and to examine neurocognitive predictors of treatment response. Thirty-two subjects (29 female subjects [90.6%]; mean age, 32.8 ± 13.3 years) with PSP were treated in a 12-week randomized, double-blind, placebo-controlled trial of lamotrigine as monotherapy. Baseline cognitive assessment comprised the stop signal and intradimensional/extradimensional set shift tasks. Lamotrigine dosing ranged from 12.5 to 300 mg/d. The primary outcome measure was picking symptoms measured by the Yale-Brown Obsessive Compulsive scale Modified for Neurotic Excoriation. Subjects also were assessed with measures of psychosocial functioning. No significant overall differences were noted between lamotrigine and placebo on the primary or secondary end points. Seven subjects assigned to lamotrigine (43.8%) were considered responders (defined as ≤35% n the Yale-Brown Obsessive Compulsive scale Modified for Neurotic Excoriation) compared with 5 (31.3%) assigned to placebo. Those who ultimately responded to lamotrigine exhibited impaired cognitive flexibility (extradimensional shifting) at baseline compared with lamotrigine nonresponders. These findings suggest that, although safe and well tolerated, lamotrigine treatment may not be efficacious in patients with PSP as a whole, compared with placebo. However, these neurocognitive data suggest that lamotrigine may be valuable in a subset of patients who exhibit relatively impaired cognitive flexibility.

cognition, compulsion, glutamate, impulse control disorder, inhibition, neurotic excoriation, pharmacology, skin picking, treatment
0271-0749
396-403
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Odlaug, Brian L.
f021d299-d250-44a2-bb17-6f7e16bfa0f6
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Kim, Suck Won
7906e44a-fb69-403c-b7ff-c37a1c2cf7e3
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Odlaug, Brian L.
f021d299-d250-44a2-bb17-6f7e16bfa0f6
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Kim, Suck Won
7906e44a-fb69-403c-b7ff-c37a1c2cf7e3

Grant, Jon E., Odlaug, Brian L., Chamberlain, Samuel R. and Kim, Suck Won (2010) A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. Journal of Clinical Psychopharmacology, 30 (4), 396-403. (doi:10.1097/JCP.0b013e3181e617a1).

Record type: Article

Abstract

Although a relatively common behavior, treatment data for pathological skin picking (PSP) are limited. The current study sought to examine the efficacy and tolerability of lamotrigine in adults with PSP and to examine neurocognitive predictors of treatment response. Thirty-two subjects (29 female subjects [90.6%]; mean age, 32.8 ± 13.3 years) with PSP were treated in a 12-week randomized, double-blind, placebo-controlled trial of lamotrigine as monotherapy. Baseline cognitive assessment comprised the stop signal and intradimensional/extradimensional set shift tasks. Lamotrigine dosing ranged from 12.5 to 300 mg/d. The primary outcome measure was picking symptoms measured by the Yale-Brown Obsessive Compulsive scale Modified for Neurotic Excoriation. Subjects also were assessed with measures of psychosocial functioning. No significant overall differences were noted between lamotrigine and placebo on the primary or secondary end points. Seven subjects assigned to lamotrigine (43.8%) were considered responders (defined as ≤35% n the Yale-Brown Obsessive Compulsive scale Modified for Neurotic Excoriation) compared with 5 (31.3%) assigned to placebo. Those who ultimately responded to lamotrigine exhibited impaired cognitive flexibility (extradimensional shifting) at baseline compared with lamotrigine nonresponders. These findings suggest that, although safe and well tolerated, lamotrigine treatment may not be efficacious in patients with PSP as a whole, compared with placebo. However, these neurocognitive data suggest that lamotrigine may be valuable in a subset of patients who exhibit relatively impaired cognitive flexibility.

This record has no associated files available for download.

More information

Published date: August 2010
Keywords: cognition, compulsion, glutamate, impulse control disorder, inhibition, neurotic excoriation, pharmacology, skin picking, treatment

Identifiers

Local EPrints ID: 492851
URI: http://eprints.soton.ac.uk/id/eprint/492851
ISSN: 0271-0749
PURE UUID: 1d39bcf9-635f-45f9-aeb2-7f2ea71818f2
ORCID for Samuel R. Chamberlain: ORCID iD orcid.org/0000-0001-7014-8121

Catalogue record

Date deposited: 15 Aug 2024 17:04
Last modified: 30 Aug 2024 02:00

Export record

Altmetrics

Contributors

Author: Jon E. Grant
Author: Brian L. Odlaug
Author: Samuel R. Chamberlain ORCID iD
Author: Suck Won Kim

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×